South Tyneside and Sunderland NHS Foundation Trust patients are being enrolled in two urgent public health research studies set up by the National Institute for Health Research.
As yet, there are no proven treatments for covid-19 but, using international evidence and UK expertise, the most promising potential treatments have been identified and these national clinical trials aim to establish their effectiveness.
The hospital-based research trials at South Tyneside District Hospital and Sunderland Royal Hospital - RECOVERY and REMAP-CAP - are being led by consultant respiratory physician Dr Liz Fuller and consultant in anaesthesia and intensive care Dr Alistair Roy respectively, with support from the trust’s research team.
South Shields man left devastated by fibromyalgia and arthritis sets up new support group to help men talk about their health
'Thousands' may have long Covid in South Tyne
Beware of jellyfish - here's what to do if you are stung by one in South Tyneside
Monkeypox, Covid, flu and hayfever - here's how to tell the difference in the early stages of infection
More than 30 new covid cases in South Tyneside but no more virus-related deaths
The RECOVERY trial involves patients in hospital with confirmed covid-19 and aims to identify treatments that may help their recovery.
Led by the University of Oxford, the trial is testing four suggested treatments for covid-19 – two antiretroviral drugs commonly used to treat HIV, a type of steroid used in a range of conditions, typically to reduce inflammation; a medicine related to an anti-malarial drug, and a commonly used antibiotic.
Data from the trial will be regularly reviewed so that any effective treatment can be identified quickly and made available to all patients and information on new drugs will be considered with a view to including the promising ones in the trial.
REMAP-CAP is an international trial focusing on critically ill patients with community-acquired pneumonia (or CAP), which is a significant cause of hospitalisation and illness world-wide.
Two covid-19-specific elements have been added to the trial - antiviral therapy and immune modulation therapy (medications that alter the way that the immune system works).
Dr Fuller said: “We are proud to be one of the trusts across the country taking part in the RECOVERY trial and helping to establish potential treatments for covid-19 as quickly as possible.”
Dr Roy added: "Quality research, like the REMAP-CAP and RECOVERY studies, help us to develop future care for patients.
“It is only through such studies that we can continue to provide the best evidence-based care which our patients deserve."
South Tyneside and Sunderland NHS Foundation Trust is also involved in two further covid-19 studies which have been prioritised and fast-tracked through the set-up process.
Dr Tony Rostron, consultant in anaesthesia and intensive care medicine, is principal investigator for GenOMICC, which aims to identify the genes that cause susceptibility to covid-19 to help to prioritise treatments.
The trust’s director of research and innovation, consultant obstetrician and gynaecologist, Mr Kim Hinshaw, is principal investigator for a national trial led by the UKOSS (UK Obstetric Surveillance System) team based in Oxford, which will assess the outcomes for the mother and baby for pregnant women with COVID-19 who are admitted to hospital.
The trust is already looking at more opportunities to get involved in COVID-19 trials as they emerge.
A message from the Editor: